Detecting and preventing post-hematopoietic cell transplant relapse in AML

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Relapsed disease is the leading cause of mortality in acute myeloid leukemia (AML) patients post-allogeneic hematopoietic cell transplantation (HCT).
• Conventional relapse prediction methods based on pre-transplant diagnostics have limitations in reflecting AML's molecular complexity and treatment impacts.

Purpose of the Study:

• To review recent advancements in detecting and preventing AML relapse after allogeneic HCT.
• To highlight the evolving strategies for improving post-transplant outcomes in AML.

Main Methods:

• Review of current literature on AML relapse detection and prevention post-HCT.
• Emphasis on measurable residual disease (MRD) monitoring techniques.
• Analysis of emerging therapeutic strategies, including maintenance therapies.

Main Results:

• Measurable residual disease (MRD) techniques (flow cytometry, molecular testing) show promise for improved prognostic ability and surveillance.
• FLT3 inhibitor maintenance therapy demonstrates potential to improve post-HCT outcomes.
• Combination therapies and early MRD-directed interventions may enhance outcomes, while DNA methyltransferase inhibitor monotherapy shows less compelling results.

Conclusions:

• Post-HCT AML relapse prevention strategies are advancing with more sensitive detection methods and novel therapies.
• Incorporating MRD monitoring and exploring new therapeutic combinations are key to improving outcomes for high-risk AML patients.
• Continued research is necessary to sustain progress in preventing AML relapse after HCT.